Brian Park, PharmD

Drug Information Specialist https://www.medicalbag.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Medicine

Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results

Brian Park, PharmD

September 12, 2023

Risankizumab is an interleukin-23 antagonist; ustekinumab is an interleukin-12 and -23 antagonist.

Ophthalmology

FDA Warns Against Use of MSM-Containing Eye Drops

Brian Park, PharmD

August 30, 2023

According to the FDA, there are no legally marketed ophthalmic products that contain MSM as an active ingredient.

Womens Health

FDA Fast Tracks Novel siRNA Therapy for Preeclampsia Treatment

Brian Park, PharmD

August 29, 2023

The investigational therapy is designed to decrease the production of soluble fms-like tyrosine kinase-1 (sFLT1) mRNA isoforms in the placenta.

Endocrinology

Significant Weight Loss Observed With Tirzepatide in Two Phase 3 Studies

Brian Park, PharmD

August 7, 2023

Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Medicine

Motive Knee, a Muscle Stimulation Device for Knee Pain Relief, Now Available

Brian Park, PharmD

July 24, 2023

The Motive Knee device is intended to strengthen the quadriceps muscles using neuromuscular electrical stimulation to provide knee pain relief.

Womens Health

First Over-the-Counter Birth Control Pill Gets FDA Approval

Brian Park, PharmD

July 19, 2023

Removing the prescription requirement improves access to an effective contraceptive method for women of all ages.

Pediatrics

Empagliflozin Approved for Pediatric Patients With Type 2 Diabetes

Brian Park, PharmD

July 5, 2023

The approval of empagliflozin for pediatric T2DM was based on data from the phase 3 DINAMO trial.

Ophthalmology

Reproxalap Ophthalmic Solution Reduces Ocular Itching in Allergic Conjunctivitis Trial

Brian Park, PharmD

June 30, 2023

The phase 3 INVIGORATE-2 trial included 131 allergic conjunctivitis patients 18 years of age and older.

Oncology

FDA to Review Novel Regimen for Treating Metastatic Pancreatic Ductal Adenocarcinoma

Brian Park, PharmD

June 28, 2023

The sNDA included 770 patients who have not previously received chemotherapy for mPDAC.

Pediatrics

FDA Clears BabySat, an At-Home Pulse Oximetry Sock Device for Infants

Brian Park, PharmD

June 27, 2023

BabySat is expected to be available by prescription later this year.

Next post in Pediatrics